T-cell engager Archives - USA News Group

“Cold” Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

4503, Astellas Pharma Inc., Biopharma stocks on NASDAQ, Biopharma, Inc., GT Biopharma, GT Biopharma, Inc., GTBP, immuno-oncology, NASDAQ Stocks to buy, Oncolytics Biotech Inc., ONCY, PSMA Program, RSS, Sensei Biotherapeutics, Inc., SNSE, T-cell engager, VIR, Vir Biotechnology, Inc. May 14, 2026 World Street Intelligence

GT Biopharma announced on May 14, 2026 that the first patient has been dosed in a Phase 1 dose-escalation basket trial of GTB-5550, a B7-H3-targeted natural killer cell engager for solid tumors, with the trial spanning seven tumor types including prostate, pancreatic, ovarian, breast, head and neck, non-small cell lung, and bladder cancer.

General Disclaimer & Disclosure. USA News Group publishes sponsored and paid-for editorial content produced in the form of digital media distribution. This material is prepared and issued by USA News Group on behalf of Market Equities Limited (“Market Equities” or “MEL”), and is provided strictly for general informational and investor-awareness purposes. Nothing published by USA News Group is, or should be construed as, investment, financial, tax, accounting, or legal advice, nor as an offer, recommendation, or solicitation to buy, sell, or hold any security.
Compensation. Market Equities is engaged in the business of marketing and advertising companies for monetary compensation. Unless otherwise expressly stated in an article-specific disclaimer, Market Equities has received, or expects to receive, compensation for the production and distribution of content appearing on this website, either directly from a profiled issuer or from a third-party engaging party such as an investor-relations firm or marketing agency. The specific nature, source, and amount of compensation is set out in the disclaimer accompanying each individual article.
Ownership & Positions. Market Equities Limited, its related and affiliated entities, and their respective owners, directors, officers, employees, and affiliates may hold, acquire, or dispose of shares or other securities of the companies profiled on this website. Any such positions, and the manner in which they were acquired, are disclosed in the applicable article-specific disclaimer. These parties reserve the right to purchase or sell such securities at any time, with or without notice, which may affect the price of those securities.
No Guarantee of Accuracy. Information published on this website is obtained from sources believed to be reliable, including public disclosures, regulatory filings, and materials supplied by profiled issuers. However, neither USA News Group nor Market Equities independently verifies all such information, and neither guarantees its accuracy, completeness, or timeliness. All content is provided “as is,” and neither party assumes any obligation to update it.
Forward-Looking Statements. Content on this website may contain forward-looking statements within the meaning of applicable securities legislation. Such statements are based on current expectations and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements.
Reader Responsibility. Investing in securities, particularly small-capitalization and micro-cap issuers, carries a high degree of risk and may result in the loss of some or all of an investment. Readers should not make any investment decision based on the content of this website. Before acting on any information, readers should conduct their own due diligence and consult a licensed financial, legal, or tax professional. By accessing USA News Group, you acknowledge and agree to the terms of this disclaimer.